NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating NeuroMetrix, Inc. (NASDAQ: NURO ), relating to the proposed merger with electroCore, Inc. Under the terms of the agreement, shareholders of NeuroMetrix will be entitled to receive the equivalent of the balance of NeuroMetrix's net cash at the closing of the transaction, estimated to be $9 million in the aggregate.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQ: NURO) to electroCore, Inc. is fair to NeuroMetrix shareholders. Halper Sadeh encourages NeuroMetrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether NeuroMetrix and its board of direct.

NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders

WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix.

NeuroMetrix to be Acquired by electroCore

Despite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment.

NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth

WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.

NeuroMetrix Reiterates its Review of Strategic Alternatives

NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founder and Chief Executive Officer Conference Call Participants Jarrod Cohen - JM Cohen & Company Operator Good morning, and welcome to the NeuroMetrix Second Quarter 2024 Business and Financial Update. My name is Amy, and I will be your moderator on the call.

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024.

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.

NeuroMetrix Reports Q1 2024 Business Highlights

Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital.

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently personally paid the FTC $4 million as part of a settlement Gozani barely owns any NURO shares NURO continues to sell stock significantly below its net cash value NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Earlier today Echo Lake Capital sent a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO.

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's leadership - Sees no reason for company to remain public NEW YORK, NY / ACCESSWIRE / March 4, 2024 / On February 27, 2024, Ephraim Fields of Echo Lake Capital filed a Schedule 13D which included a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter described his belief that the company should immediately liquidate because its stock price is trading significantly below net cash and because Mr.

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic options to promote growth of its Quell® neuromodulation and DPNCheck® neurodiagnostic businesses and to maximize shareholder value.

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

NeuroMetrix announced today that the Company's Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID.

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will also be adjusted accordingly.

NeuroMetrix Announces One-for-Eight Reverse Stock Split

WOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023.

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

NeuroMetrix Inc. (NASDAQ:NURO ) Q3 2023 Results Conference Call October 26, 2023 8:00 AM ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - Chairman & CEO Operator Good morning, and welcome to NeuroMetrix Third Quarter 2023 Business and Financial Highlights Update. My name is Norma, and I'll be your moderator on the call.

NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript

WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.

NeuroMetrix Reports Q3 2023 Business Highlights

NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.

News for NeuroMetrix Stock (NURO)